Acquisition Momentum PLUS Diagnostics was recently acquired by Miraca Life Sciences, indicating a consolidation in the pathology services market and potential access to MLS’s client base, sales channels, and expanded service offerings.

Service Spectrum Strong specialization across genitourinary, gastrointestinal, dermatopathology, hematopathology, breast, and oral/maxillofacial pathology suggests cross-sell opportunities to hospitals and clinics seeking end-to-end anatomic pathology workflows.

Quality Credentials CLIA-certified, CAP-accredited and distinguished for precision position PLUS Diagnostics as a trusted partner for high-stakes diagnostic services, enabling value-based and contract-based selling with risk-sharing potential.

Financial Scale Revenue in the $10–25 million range with mid-sized employee base presents a growth pathway for larger healthcare buyers while offering a fit for regional health systems seeking scalable pathology outsourcing solutions.

Market Positioning Operating in the hospitals and health care sector with a focus on specialized pathology aligns PLUS with large reference labs and molecular pathology providers, presenting collaboration or migration opportunities for clients evaluating breadth of capabilities and turnaround time.